Evaxion Biotech As Stock Today
| EVAX Stock | USD 2.47 0.92 27.14% |
Performance0 of 100
| Odds Of DistressOver 85
|
Evaxion Biotech is trading at 2.47 as of the 31st of January 2025; that is 27.14 percent down since the beginning of the trading day. The stock's open price was 3.39. Evaxion Biotech has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 3rd of September 2024 and ending today, the 31st of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of February 2021 | Category Healthcare | Classification Health Care |
Evaxion Biotech AS, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company was incorporated in 2008 and is headquartered in Hrsholm, Denmark. The company has 5.58 M outstanding shares of which 102.32 K shares are currently shorted by private and institutional investors with about 2.07 trading days to cover. More on Evaxion Biotech AS
Moving together with Evaxion Stock
Moving against Evaxion Stock
| 0.64 | MLAB | Mesa Laboratories Earnings Call This Week | PairCorr |
| 0.53 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
| 0.36 | GILD | Gilead Sciences Earnings Call This Week | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Evaxion Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEvaxion Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Evaxion Biotech's financial leverage. It provides some insight into what part of Evaxion Biotech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evaxion Biotech AS (EVAX) is traded on NASDAQ Exchange in USA. It is located in Dr. Neergaards Vej, Horsholm, Denmark, 2970 and employs 49 people. Evaxion Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.28 M. Evaxion Biotech AS conducts business under Biotechnology sector and is part of Health Care industry. The entity has 5.58 M outstanding shares of which 102.32 K shares are currently shorted by private and institutional investors with about 2.07 trading days to cover.
Evaxion Biotech AS currently holds about 25.25 M in cash with (17.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.06.
Check Evaxion Biotech Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Evaxion Biotech AS is $13.28 Million. Evaxion Biotech AS retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Evaxion Ownership Details
Evaxion Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Armistice Capital, Llc | 2024-09-30 | 483 K | |
| Invst Llc | 2024-09-30 | 43.2 K | |
| Citadel Advisors Llc | 2024-09-30 | 14.8 K | |
| Beacon Capital Management, Llc | 2024-09-30 | 4.9 K | |
| Blackrock Inc | 2024-09-30 | 1.5 K | |
| Jpmorgan Chase & Co | 2024-09-30 | 780 | |
| Rhumbline Advisers | 2024-09-30 | 290 | |
| Southstate Corp | 2024-09-30 | 4.0 | |
| Tower Research Capital Llc | 2024-06-30 | 0.0 |
Evaxion Biotech Historical Income Statement
Evaxion Stock Against Markets
Evaxion Biotech Corporate Management
| DMSC MD | Chief Officer | Profile | |
| Christian MSc | Chief Officer | Profile | |
| Jrgen EMBA | Head Board | Profile | |
| Bo Karmark | Chief Officer | Profile | |
| Jesper Nissen | Chief Officer | Profile | |
| Thomas Schmidt | Interim Officer | Profile |
Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.